RxDoctor Payments Data

James Whited

Family · Jacksonville, FLNPI 1457668618

Payments from drug & device makers

$1,171in general payments, 2019–2025

Across 63 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$428
  • Sunovion Pharmaceuticals Inc.$186
  • Lilly USA, LLC$180
  • AbbVie$102
  • Boehringer Ingelheim$87
  • Novo Nordisk$54
  • plus $133 from 6 others

What the payments were for

  • Food & beverage$1,171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,171 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$106,110
Medicare patients
69
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide180$198,978
TrulicityDulaglutide99$88,788
OzempicSemaglutide24$20,549
TrintellixVortioxetine Hydrobromide12$5,974
Sirolimus19$4,905
Roflumilast11$3,252
Varenicline Tartrate12$2,632
Quetiapine Fumarate ErQuetiapine Fumarate16$1,653
Quetiapine Fumarate53$1,644
Gemfibrozil113$725
Topiramate104$604
Ondansetron OdtOndansetron19$579
Metformin Hcl240$565
Buspirone Hcl75$484
Anastrozole40$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$180$288,028292 claims
Novo NordiskOzempic$54$20,54924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →